Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pamufetinib - Taiho Pharmaceutical

Next Previous
Drug Profile

Pamufetinib - Taiho Pharmaceutical

Alternative Names: TAS-115

Latest Information Update: 17 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taiho Pharmaceutical
  • Class Amides; Antifibrotics; Antineoplastics; Fluorobenzenes; Quinolines; Small molecules; Thiones
  • Mechanism of Action Hepatocyte growth factor inhibitors; Proto-oncogene protein c-met inhibitors; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Osteosarcoma
  • Phase II Idiopathic pulmonary fibrosis; Interstitial lung diseases; Prostate cancer
  • Phase I Solid tumours

Most Recent Events

  • 17 May 2025 Efficacy and adverse event data from the phase II trial in Interstitial lung diseases presented at the 121st International Conference of the American Thoracic Society 2025 (ATS-2025)
  • 17 May 2025 Taiho Pharmaceutical completes the Phase-II clinical trials in Interstitial lung diseases in Japan (PO) prior to May 2025 (jRCT2051210050)
  • 30 Sep 2023 Phase-I clinical trials in Solid tumours (Combination therapy with zimberelimab) in Japan prior to September 2023 (PO) (Otsuka Pharmaceutical pipeline, November 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top